Research programme: cannabinoid receptor agonists - MakScientific/Endo Pharmaceuticals
Latest Information Update: 07 Feb 2008
At a glance
- Originator MakScientific
- Developer Endo Pharmaceuticals
- Mechanism of Action Cannabinoid receptor CB2 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued CNS disorders; Pain
Most Recent Events
- 08 Mar 2004 Preclinical trials in CNS disorders in USA (unspecified route)
- 08 Mar 2004 Preclinical trials in Pain in USA (unspecified route)